Anhui Huaheng Biotechnology Co. Ltd. A - Asset Resilience Ratio
Anhui Huaheng Biotechnology Co. Ltd. A (688639) has an Asset Resilience Ratio of 0.71% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anhui Huaheng Biotechnology Co. Ltd. A (688639) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2022)
This chart shows how Anhui Huaheng Biotechnology Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Anhui Huaheng Biotechnology Co. Ltd. A.
Liquid Assets Composition Over Time
This chart breaks down Anhui Huaheng Biotechnology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Anhui Huaheng Biotechnology Co. Ltd. A (688639) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥20.00 Million | 0.71% |
| Total Liquid Assets | CN¥20.00 Million | 0.71% |
Asset Resilience Insights
- Limited Liquidity: Anhui Huaheng Biotechnology Co. Ltd. A maintains only 0.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anhui Huaheng Biotechnology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Anhui Huaheng Biotechnology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Anhui Huaheng Biotechnology Co. Ltd. A (2021–2022)
The table below shows the annual Asset Resilience Ratio data for Anhui Huaheng Biotechnology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 9.88% | CN¥200.31 Million ≈ $29.31 Million |
CN¥2.03 Billion ≈ $296.63 Million |
-13.26pp |
| 2021-12-31 | 23.14% | CN¥341.06 Million ≈ $49.91 Million |
CN¥1.47 Billion ≈ $215.71 Million |
-- |
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material mon… Read more